Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s Why

Seres Therapeutics, Inc. (NASDAQ:MCRB) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $17.17 and traded as low as $14.49. Seres Therapeutics shares last traded at $15.00, with a volume of 52,275 shares changing hands.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday. Canaccord Genuity Group boosted their price target on shares of Seres Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $14.33.

Seres Therapeutics Trading Up 2.6%

The firm has a market cap of $139.32 million, a P/E ratio of -4.31 and a beta of 0.18. The business’s fifty day simple moving average is $17.09 and its 200-day simple moving average is $15.79.

Institutional Trading of Seres Therapeutics

Large investors have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 5,157 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of Seres Therapeutics during the third quarter valued at approximately $557,000. Vanguard Group Inc. lifted its holdings in shares of Seres Therapeutics by 6.8% during the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock valued at $6,001,000 after purchasing an additional 19,793 shares during the last quarter. Vontobel Holding Ltd. boosted its position in shares of Seres Therapeutics by 22.6% in the 3rd quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company’s stock worth $1,895,000 after purchasing an additional 18,186 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Seres Therapeutics during the 2nd quarter valued at approximately $1,016,000. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.